Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
ACRV 
Acrivon Therapeutics, Inc. Common Stock (ACRV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/02/2026: ACRV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.17
1 Year Target Price $11.17
| 4 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.72% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/02/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.63M USD | Price to earnings Ratio - | 1Y Target Price 11.17 |
Price to earnings Ratio - | 1Y Target Price 11.17 | ||
Volume (30-day avg) 9 | Beta 1.77 | 52 Weeks Range 1.05 - 8.00 | Updated Date 01/3/2026 |
52 Weeks Range 1.05 - 8.00 | Updated Date 01/3/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.89% | Return on Equity (TTM) -50.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -48639391 | Price to Sales(TTM) - |
Enterprise Value -48639391 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 31555126 | Shares Floating 16857064 |
Shares Outstanding 31555126 | Shares Floating 16857064 | ||
Percent Insiders 20.57 | Percent Institutions 56.11 |
Upturn AI SWOT
Acrivon Therapeutics, Inc. Common Stock
Company Overview
History and Background
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018. It is focused on developing novel precision oncology therapies. Significant milestones include its IPO in February 2024 and progress in its clinical trials for its lead drug candidates.
Core Business Areas
- Oncology Drug Development: Acrivon Therapeutics is dedicated to the discovery and development of targeted therapies for cancer patients. Their platform aims to identify patient populations most likely to respond to specific treatments.
Leadership and Structure
Acrivon Therapeutics is led by a management team with experience in biotechnology and drug development. The company is structured around its research and development activities, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Arid-1a Inhibitor Program (ACR-16): A first-in-class inhibitor targeting ARID1A mutations, which are prevalent in several challenging-to-treat cancers such as ovarian, bladder, and endometrial cancers. Competitors in the broader oncology space include major pharmaceutical companies and other emerging biotechs developing targeted therapies. Specific market share data for this early-stage program is not yet available.
- ARID1B Inhibitor Program (ACR-26): Another novel program targeting ARID1B, a protein closely related to ARID1A, with potential applications in various solid tumors. Similar to ACR-16, specific market share data is not yet available.
Market Dynamics
Industry Overview
The precision oncology market is a rapidly growing segment of the pharmaceutical industry, driven by advances in genomic sequencing and a better understanding of cancer biology. The demand for targeted therapies that offer improved efficacy and reduced toxicity is high.
Positioning
Acrivon Therapeutics is positioned as a pioneer in developing therapies for ARID1-mutated cancers, a previously undruggable target. Their proprietary technology platform aims to identify patient responders, providing a competitive advantage in a crowded oncology landscape.
Total Addressable Market (TAM)
The TAM for oncology is substantial and growing. For specific ARID1-mutated cancers, the addressable market is significant, with millions of patients globally diagnosed with these types of tumors. Acrivon is focused on capturing a meaningful share of this segment through its innovative approach.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting a previously undruggable pathway (ARID1 mutations).
- Proprietary technology platform for identifying patient responders.
- Experienced management team with a strong scientific background.
- Clinical-stage development indicating progress towards market.
Weaknesses
- Early-stage company with no approved products.
- High dependence on the success of its lead drug candidates.
- Limited financial resources compared to established pharmaceutical companies.
- Clinical trial risks and regulatory hurdles.
Opportunities
- Significant unmet medical need in ARID1-mutated cancers.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical companies.
- Expansion of their platform technology to other targets.
- Growing investor interest in innovative oncology treatments.
Threats
- Competition from other companies developing similar targeted therapies.
- Clinical trial failures or unexpected side effects.
- Regulatory delays or rejections.
- Changes in healthcare policies and reimbursement.
Competitors and Market Share
Key Competitors
- Puma Biotechnology, Inc. (PBYI)
- Verastem, Inc. (VSTM)
- Mirati Therapeutics Inc. (MRTX) (Acquired by BMS)
- Pfizer Inc. (PFE)
- Novartis AG (NVS)
Competitive Landscape
Acrivon's competitive advantage lies in its focus on the ARID1 pathway, which is relatively underexplored by many competitors. However, it faces formidable competition from large pharmaceutical companies with extensive resources and established market presence in the broader oncology sector. Its success hinges on demonstrating superior efficacy and safety profiles for its novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Acrivon's growth trajectory has been marked by its transition from a private research entity to a publicly traded company, reflecting advancements in its drug development pipeline.
Future Projections: Future growth is contingent on the successful clinical development and potential commercialization of its lead drug candidates, ACR-16 and ACR-26. Analyst projections will heavily depend on clinical trial outcomes and market adoption.
Recent Initiatives: Key recent initiatives include advancing its lead drug candidates into clinical trials, strengthening its management team, and raising capital through its IPO.
Summary
Acrivon Therapeutics is an early-stage biopharmaceutical company with promising novel drug candidates in precision oncology. Its strengths lie in its unique scientific approach and experienced team, while its weaknesses stem from its clinical-stage nature and reliance on future trial success. The company has significant opportunities in a growing market but must navigate intense competition and the inherent risks of drug development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q, S-1)
- Financial news outlets
- Industry analysis reports
- Biopharmaceutical industry databases
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information is based on publicly available data and may not be exhaustive. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acrivon Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2022-11-15 | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://acrivon.com |
Full time employees 75 | Website https://acrivon.com | ||
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.